Bipolar disorder (BD) and schizophrenia (SCZ) are severe mental illness (SMI) syndromes with a median lifetime prevalence of 2.4 and 3.3 per thousand persons, respectively,[1](#pcn12788-bib-0001){ref-type="ref"}, [2](#pcn12788-bib-0002){ref-type="ref"} and an estimated heritability of 70--90%.[3](#pcn12788-bib-0003){ref-type="ref"}, [4](#pcn12788-bib-0004){ref-type="ref"} Evidence from family and molecular genetic studies suggests shared, perhaps overlapping, risk factors across these syndromes.[5](#pcn12788-bib-0005){ref-type="ref"}, [6](#pcn12788-bib-0006){ref-type="ref"} The outcomes from large‐scale genome‐wide association studies (GWAS) exploring the common disease--common variant (CDCV) hypothesis detect a proportion of the estimated genetic risk.[7](#pcn12788-bib-0007){ref-type="ref"} In this context, next‐generation sequencing (NGS) technology, by evaluating rare genetic variants, has enabled a deeper examination of complex traits using alternate models of risk, such as the 'oligogenic quasi‐Mendelian model'[8](#pcn12788-bib-0008){ref-type="ref"} and the 'omnigenic models'[9](#pcn12788-bib-0009){ref-type="ref"} of inheritance. Several recent studies in autism, SCZ, BD, and depression have detected rare variants using NGS in case--control or family‐based designs, across different genes implicated to play a key role in critical biological pathways.[10](#pcn12788-bib-0010){ref-type="ref"}, [11](#pcn12788-bib-0011){ref-type="ref"} Findings from such studies have shown that the majority of the rare variants identified are private to a family (Table S1),[12](#pcn12788-bib-0012){ref-type="ref"}, [13](#pcn12788-bib-0013){ref-type="ref"}, [14](#pcn12788-bib-0014){ref-type="ref"} indicating the underlying heterogeneity in the genetic architecture of SMI. Multiplex families may provide valuable insights into the genetic correlates of these syndromes[15](#pcn12788-bib-0015){ref-type="ref"}, [16](#pcn12788-bib-0016){ref-type="ref"} when tested using high throughput sequencing.

A cross‐nosology approach has been quite informative in identifying potential disease‐relevant pathways in SCZ and BD.[17](#pcn12788-bib-0017){ref-type="ref"}, [18](#pcn12788-bib-0018){ref-type="ref"} Single‐nucleotide polymorphisms (SNP) associated with these two syndromes show a high mutual correlation, among combinations of neuropsychiatric syndromes.[7](#pcn12788-bib-0007){ref-type="ref"} Such overlaps have also been observed across diverse neuropsychiatric syndromes, for both common and rare genetic variations, as well as in gene expression profiles in the cerebral cortex.[19](#pcn12788-bib-0019){ref-type="ref"}, [20](#pcn12788-bib-0020){ref-type="ref"} These findings indicate an underlying shared molecular pathology in the pathobiology of SMI.

As part of a longitudinal study, 'Accelerator Program for Discovery of Brain Disorders Using Stem Cells' (ADBS),[21](#pcn12788-bib-0021){ref-type="ref"} aimed at understanding the developmental trajectories and basic biology of SMI, we describe in this study the results of a variant discovery analysis using whole‐exome sequencing (WES) in eight multiplex pedigrees with SCZ and BD phenotypes from a well characterized Indian cohort. Such studies have been predominantly conducted in large cohorts of European origin,[16](#pcn12788-bib-0016){ref-type="ref"} and representation from other populations is perhaps necessary to validate earlier findings, and identify population‐specific signatures underlying SMI. In the current study, we aimed to identify rare, damaging, exonic variants that co‐segregate with SMI in multiplex families, and to examine their relevance to the disease.

Methods {#pcn12788-sec-0006}
=======

Sample selection {#pcn12788-sec-0007}
----------------

The families were recruited as part of the ADBS longitudinal study, which has been approved by the ethics committee of the National Institute of Mental Health and Neurosciences, Bengaluru, India. The details of screening, informed consent, recruitment, and phenotyping have been previously published.[21](#pcn12788-bib-0021){ref-type="ref"} Some of the families in the cohort have been on follow up for longer than 10 years. We have previously noted evidence of linkage in psychosis at chromosome 18p11.2,[22](#pcn12788-bib-0022){ref-type="ref"} and the sex‐specific association to the *DISC1* gene using a case--control study design[23](#pcn12788-bib-0023){ref-type="ref"} in samples taken from this cohort. For the current study, eight families (A through H) with high loading of SMI (SCZ, BD, and psychosis in the context of these eight pedigrees; Fig. [1](#pcn12788-fig-0001){ref-type="fig"}a, Fig. S1) were assessed in detail. From these, 32 individuals ('cases'; 16 females) with SMI were available for blood sampling and were subjected to WES. Two senior psychiatrists evaluated all patients and unaffected relatives independently. Diagnoses were made with the ICD‐10 Classification for Mental and Behavioural Disorders and were verified in the longitudinal course of follow ups. From five of the eight families, we could also sample eight unaffected individuals who had crossed the age at risk and are defined as a 'family‐specific control' for the respective pedigree henceforth in this report. An independent set of 25 individuals without a history of SMI were further sampled as population‐matched controls. Together this group constituted a total of 33 asymptomatic 'controls.'

![(a) Two representative pedigrees analyzed with exome sequencing (Families A and B). (b) Cluster dendrogram created with a distance matrix based on the degree of variant sharing between pairs of cases and controls analyzed in the study. (c) 'varPrio' -- variant prioritization pipeline with numbers indicating the reduction in the total number of variants in each prioritization step. (d) Ideogram representing the 42 genes that harbored variants prioritized by non‐synonymous damaging strict (NSD‐S) and disruptive definition generated with NCBI genome decoration page.](PCN-73-11-g001){#pcn12788-fig-0001}

Exome sequencing and analysis {#pcn12788-sec-0008}
-----------------------------

Sequencing was carried out on the Illumina Hiseq NGS platform with libraries prepared using Illumina exome kits. Reads were aligned with reference human genome GRCh37 using the Burrows--Wheeler algorithm tool.[24](#pcn12788-bib-0024){ref-type="ref"} Variants were called from realigned BAM files using Varscan2 with the standard criteria (min coverage = 8, MAF ≥ 0.25, and *P* ≤ 0.001).[25](#pcn12788-bib-0025){ref-type="ref"} Standard quality control protocols were employed at sequencing, alignment, and variant calling (Fig.S2). The resulting variant called files were annotated with ANNOVAR.[26](#pcn12788-bib-0026){ref-type="ref"}

Pedigree‐based analysis {#pcn12788-sec-0009}
-----------------------

All variant segregation analysis was performed at the level of individual pedigrees. To ascertain the degree of variance (between pedigrees) and relatedness within family structures, we generated a dendrogram with hierarchical clustering analysis using an allele‐sharing matrix of the exonic variants (Appendix [S1](#pcn12788-supitem-0001){ref-type="supplementary-material"}).

Variant prioritization {#pcn12788-sec-0010}
----------------------

Variants were prioritized if:the variant was found to be shared by all affected individuals within the pedigree while allowing for one missing genotype, a method shown to be useful in an earlier study of familial BD[12](#pcn12788-bib-0012){ref-type="ref"};the variant fell into any of the following deleterious categories -- the non‐synonymous damaging strict (NSD‐S) set predicted to be damaging by five prediction algorithms (SIFT,[27](#pcn12788-bib-0027){ref-type="ref"} Polyphen‐2 HDIV,[28](#pcn12788-bib-0028){ref-type="ref"} Mutation taster 2,[29](#pcn12788-bib-0029){ref-type="ref"} Mutation assessor,[30](#pcn12788-bib-0030){ref-type="ref"} and LRT[31](#pcn12788-bib-0031){ref-type="ref"}\[Appendix S1\]), the Disruptive set predicted to result in protein truncation (splice site, stop gain, or stop loss variants), or the non‐synonymous damaging broad (NSD‐B) set predicted to be damaging by one or more of the five prediction algorithms; andthe variant was rare \<1% in Exome Aggregation Consortium -- South Asian sample (ExAC‐SAS)[32](#pcn12788-bib-0032){ref-type="ref"} and completely absent from a control cohort of 33 individuals from the same gene pool (<http://indexdb.ncbs.res.in>).

The above variant prioritization was carried out using an in‐house automated pipeline 'varPrio'. Details of the pipeline and the resulting variant enrichment are summarized in Figure[1](#pcn12788-fig-0001){ref-type="fig"}c. To rule out any false positive calls at the final variant list, a representative set of prioritized variants (*n*=10) was independently confirmed by Sanger sequencing and we noted a 100% concordance.

Functional annotation {#pcn12788-sec-0011}
---------------------

We adapted two approaches for evaluating functional impact to the prioritized variants:We reviewed the literature on individual genes identified in the NSD‐S and the disruptive set carrying rare variants of highest priority (all five *in silico* predictors) for prior evidence of disease association in neuropsychiatric phenotype.For the NSD‐B set carrying rare variants of plausible disease relevance (1--5 *in silico* predictors), we tested for enrichment of the aggregate list using DAVID functional annotation tool 6.8.[33](#pcn12788-bib-0033){ref-type="ref"}, [34](#pcn12788-bib-0034){ref-type="ref"} To test the enrichment on the categories of biological process, molecular function, protein domain, protein--protein interaction, and tissue expression we selected the sources as --'GOTERM_BP_DIRECT', 'GOTERM_MF_DIRECT', 'INTERPRO', 'KEGG_PATHWAY' and'UP_TISSUE' in this *in silico* approach. Modified Fisher\'s exact test with Benjamini--Hochberg correction built‐in to this algorithm was used to infer enrichment.

Results {#pcn12788-sec-0012}
=======

Sample characteristics {#pcn12788-sec-0013}
----------------------

Of the 32 cases sequenced in the study, 26 were diagnosed with BD, four with SCZ, and one each with SCZ‐like psychosis and schizoaffective disorder. They had been ill for a mean (SD) duration of 23.7 (11.1) years, and the mean (SD) age at onset was 23.1 (7.9) years. In most of the pedigrees, there was heterogeneity in the age of onset, illness severity, global outcomes, and segregation of suicidality and psychosis (in BD) with the primary phenotype. Substance use disorder was a common comorbidity, followed by hypothyroidism, seizure disorder, and dementia (Appendix [S2](#pcn12788-supitem-0002){ref-type="supplementary-material"}, Table S2).

In the analysis of relatedness using the cluster dendrogram, 'cases' and 'controls' formed a single cluster possibly resulting from sharing of a large number of common and/or benign exonic variants. As expected, members from each pedigree clustered together due to the relatively larger magnitude of variant sharing (Fig. [1](#pcn12788-fig-0001){ref-type="fig"}b, Appendix S1).

Rare deleterious variants in Mendelian genes segregate within SMI families {#pcn12788-sec-0014}
--------------------------------------------------------------------------

Familywise prioritization identified a total of 39 NSD‐S, three disruptive, and 248 NSD‐B variants. The NSD‐S and disruptive sets of variants (Table [1](#pcn12788-tbl-0001){ref-type="table"}, Fig. [1](#pcn12788-fig-0001){ref-type="fig"}d) spanning 42 genes were private to individual pedigrees (\~5 variants per pedigree). Twelve of these were novel (not reported in dbSNP or other published databases) and the remaining were noted in very low frequencies (\<1e −07 to 7.8e‐03) in ExAC‐SAS. None of the variants prioritized were present in 33 healthy Indian control samples (<http://indexdb.ncbs.res.in>). Nine (21.4%) of the 42 variants were found in genes that have been reported in Mendelian syndromes with early onset neurodevelopmental features, such as infantile epilepsy, intellectual disability, and structural brain abnormalities. Seven (16.67%) of these gene‐phenotype relationships were reported in the Online Mendelian Inheritance in Man (OMIM)[35](#pcn12788-bib-0035){ref-type="ref"} and the remaining two were noted in the MedGen (NCBI) and ClinVar[36](#pcn12788-bib-0036){ref-type="ref"} databases. This was significantly higher in comparison to a background list of 1310 out of 15 857 (8.26%) such genes (Appendix S1) listed in the OMIM database (*P* = 0.039, odds ratio \[OR\] = 2.423, confidence interval \[CI\] = 1.07--5.513, Fisher\'s exact test) while not accounting for potential gene length bias. Some of these variants were observed in close proximity to reported 'pathogenic' mutation of the relevant Mendelian syndrome and/or in highly conserved regions (Table [2](#pcn12788-tbl-0002){ref-type="table"}(a)). Two of these nine variants, one each on the *GRM1* gene (chr6:146351218, GRCh37) and *NIPBL* gene (chr5:37010263, GRCh37), were novel. Pathogenic mutations on the *GRM1* gene, coding for metabotropic glutamate receptor 1 (mGluR1) result in autosomal dominant (type 44) (OMIM:617691) and recessive (type 13) (OMIM:614831) forms of spinocerebellar ataxia, both of which are characterized by early age of onset and associated intellectual disability. Missense variants have been identified spanning the entire exome of this gene in individuals and families with SCZ and other neuropsychiatric syndromes.[37](#pcn12788-bib-0037){ref-type="ref"} Mutations in the *NIPBL* gene, coding for Cohesin Loading Factor involved cortical neuronal migration,[38](#pcn12788-bib-0038){ref-type="ref"} cause Cornelia de Lange syndrome 1. The novel missense variant identified in the pedigree G (chr5:37010263), segregating with BD would result in substitution of polar amino acid glutamine by a hydrophobic amino acid proline. A non‐sense mutation at the same codon (rs797045760) is reported to be pathogenic of Cornelia de Lange syndrome 1 (ClinVarSCV000248215.1).

###### 

List of novel or rare variants prioritized by non‐synonymous damaging strict and disruptive definition

  Gene symbol   rsID/novel    chr:location      Transcript     Exon     Variant     Amino acid change   ExAC_SAS
  ------------- ------------- ----------------- -------------- -------- ----------- ------------------- -----------
  *LRRC8B*      NOVEL         chr1:90049348     NM_015350      Exon5    c.A1139C    p.Y380S             
  *GRM1*        NOVEL         chr6:146351218    NM_001278064   Exon1    c.A565G     p.S189G             
  *SETD6*       NOVEL         chr16:58552094    NM_001160305   Exon6    c.C932G     p.A311G             
  *SYF2*        NOVEL         chr1:25555567     NM_015484      Exon3    c.A180C     p.K60N              
  *RAB3IL1*     NOVEL         chr11:61675047    NM_001271686   Exon3    c.G491A     p.S164N             
  *BCDIN3D*     NOVEL         chr12:50236792    NM_181708      Exon1    c.G79A      p.G27S              
  *NDRG3*       NOVEL         chr20:35317139    NM_022477      Exon3    c.G106T     p.G36C              
  *PARP14*      NOVEL         chr3:122423522    NM_017554      Exon8    c.G3467A    p.S1156N            
  *NIPBL*       NOVEL         chr5:37010263     NM_015384      Exon21   c.A4496C    p.Q1499P            
  *SCUBE3*      NOVEL         chr6:35211460     NM_001303136   Exon16   c.C1996T    p.L666F             
  *NBPF11*      NOVEL         chr1:147599423    Splicing                                                
  *CKMT2*       NOVEL         chr5:80550306     Splicing                                                
  *KRT85*       rs112554450   chr12:52758810    NM_002283      Exon2    c.G565A     p.D189N             6.000E‐03
  *NRG2*        rs148371256   chr5:139231286    NM_001184935   Exon7    c.C1477T    p.R493W             5.000E‐04
  *MDN1*        rs148868949   chr6:90397121     NM_014611      Exon68   c.C11392T   p.R3798W            3.000E‐03
  *MYO1A*       rs151269703   chr12:57431355    NM_005379      Exon19   c.A2032T    p.I678F             5.500E‐03
  *EFHC1*       rs1570624     chr6:52319050     NM_018100      Exon5    c.G881A     p.R294H             5.100E‐03
  *CNGB1*       rs192843629   chr16:57950041    NM_001286130   Exon22   c.C2191T    p.R731C             7.000E‐04
  *PCCB*        rs371155999   chr3:136002730    NM_000532      Exon6    c.C595T     p.P199S             7.100E‐03
  *TRMT44*      rs373816157   chr4:8467199      NM_152544      Exon8    c.C1405T    p.R469W             0.000E+00
  *CLUAP1*      rs531380218   chr16:3558347     NM_015041      Exon4    c.C278T     p.A93V              9.000E‐04
  *GOLM1*       rs534059912   chr9:88661389     NM_016548      Exon5    c.G463A     p.D155N             3.700E‐03
  *LGALS12*     rs534811017   chr11:63277314    NM_001142537   Exon3    c.C320T     p.T107M             2.200E‐03
  *ADPRH*       rs547308034   chr3:119301144    NM_001291949   Exon2    c.T128C     p.L43S              7.800E‐03
  *FAM208B*     rs548531206   chr10:5789582     NM_017782      Exon15   c.T4198C    p.S1400P            4.000E‐03
  *PM20D1*      rs553380022   chr1:205809408    NM_152491      Exon10   c.G1088A    p.R363Q             2.700E‐03
  *CD1D*        rs569233577   chr1:158152752    NM_001766      Exon5    c.C692G     p.P231R             1.400E‐03
  *PLXND1*      rs569306898   chr3:129279222    NM_015103      Exon31   c.G5084C    p.R1695P            6.124E‐05
  *WDFY4*       rs571808731   chr10:50030541    NM_020945      Exon35   c.C5941A    p.P1981T            3.100E‐03
  *CC2D2A*      rs574421639   chr4:15559035     NM_001080522   Exon22   c.A2734G    p.R912G             1.300E‐03
  *ANLN*        rs575071809   chr7:36435984     NM_001284301   Exon2    c.C128T     p.P43L              1.800E‐03
  *PARVB*       rs575240566   chr22:44528830    NM_001243385   Exon6    c.C463A     p.H155N             1.000E‐04
  *DOCK5*       rs61732769    chr8:25174610     NM_024940      Exon14   c.C1406T    p.T469M             4.300E‐03
  *KIF7*        rs749711306   chr15:90176400    NM_198525      Exon13   c.G2690C    p.G897A             6.478E‐05
  *C20orf194*   rs750188084   chr20:3251118     NM_001009984   Exon30   c.A2741G    p.N914S             6.063E‐05
  *TCEA3*       rs753347636   chr1:23720470     NM_003196      Exon8    c.C721T     p.R241C             6.058E‐05
  *ARHGEF40*    rs756016433   chr14:21553914    NM_001278529   Exon19   c.C1885T    p.R629W             0.000E+00
  *PLB1*        rs760022335   chr2:28814039     Splicing                                                0.0004
  *SCN3A*       rs775711350   chr2:166032822    NM_001081676   Exon3    c.G83A      p.R28H              0.000E+00
  *INPP5A*      rs775793924   chr10:134521844   NM_005539      Exon7    c.C502T     p.R168W             6.083E‐05
  *DENND5A*     rs779817963   chr11:9171664     NM_001243254   Exon15   c.A2699G    p.H900R             6.132E‐05
  *COL4A5*      rs78972735    chrX:107865996    NM_000495      Exon33   c.G2858T    p.G953V             6.900E‐03

Chr:location (chromosomal location); ExAC_SAS (variant allele frequency in ExAC south Asian sample).

###### 

Disease relevance of the genes harboring prioritized variants

  \(a\) Genes implicated in a Mendelian syndrome                                                                                                                                                  
  ------------------------------------------------- ---------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  *GRM1* [†](#pcn12788-note-0004){ref-type="fn"}    Glutamate metabotropic receptor 1              Spinocerebellar ataxia AR 13 (MIM:617691) and SCA 44 (MIM:614831)                              GO:0007216\~G‐protein coupled glutamate receptor signaling pathway; GO:0007268\~chemical synaptic transmission
  *EFHC1*                                           EF‐hand domain containing 1                    Myoclonic epilepsy, juvenile, susceptibility to, 1 (MIM:254770)                                GO:0021795\~cerebral cortex cell migration
  *DENND5A*                                         DENN domain containing 5A                      Epileptic encephalopathy, early infantile, 49 (MIM:617281)                                     GO:0043547\~positive regulation of GTPase activity; GO:0070588\~calcium ion transmembrane transport
  *KIF7*                                            Kinesin family member 7                        Acrocallosal syndrome, Joubert syndrome 12 (MIM:200990)                                        GO:0007018\~microtubule‐based movement; GO:0045879\~negative regulation of smoothened signaling pathway
  *SCN3A*                                           Sodium voltage‐gated channel alpha subunit 3   Cryptogeneicpaediatric partial epilepsy (Medgen CN240377)                                      GO:0019228\~neuronal action potential; GO:0060078\~regulation of postsynaptic membrane potential
  *PCCB*                                            Propionyl‐CoA carboxylase beta subunit         Propionicacidemia (MIM:606054)                                                                 GO:0006633\~fatty acid biosynthetic process
  *NIPBL* [†](#pcn12788-note-0004){ref-type="fn"}   NIPBL, cohesin loading factor                  Cornelia de Lange syndrome 1(MIM:122470)                                                       GO:0007420\~brain development; GO:0045995\~regulation of embryonic development
  *CLUAP1*                                          Clusterin‐associated protein 1                 Oculoectodermal syndrome, Joubert syndrome (ClinVar)                                           GO:0001843\~neural tube closure; GO:0021508\~floor plate formation
  *CC2D2A*                                          Coiled‐coil and C2 domain containing 2A        COACH syndrome (MIM:216360), Joubert syndrome 9 (MIM:612285), Meckel syndrome 6 (MIM:612284)   GO:1990403\~embryonic brain development; GO:0001843\~neural tube closure

  \(b\) Genes implicated in a human polygenic phenotype                                                                                                                                                                                                                                
  ------------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  *NRG2*                                                  Neuregulin 2                                Schizophrenia gamma band oscillation -- GWAS (suggestive)[39](#pcn12788-bib-0039){ref-type="ref"}                                                                                GO:0038128\~ERBB2 signaling pathway; GO:0014066\~regulation of phosphatidylinositol 3‐kinase signaling
  *GOLM1*                                                 Golgi membrane protein 1                    Alzheimer\'s dementia -- GWAS[43](#pcn12788-bib-0043){ref-type="ref"}                                                                                                            GO:0006997\~nucleus organization
  *INPP5A*                                                Inositol polyphosphate‐5‐phosphatase A      Cognitive function in older adults -- EWAS[46](#pcn12788-bib-0046){ref-type="ref"}; ataxia and cerebellar degeneration -- animal model[51](#pcn12788-bib-0051){ref-type="ref"}   GO:0048016\~inositol phosphate‐mediated signaling
  *MDN1*                                                  Midasin AAA ATPase 1                        Bipolar disorder -- Exome sequencing[44](#pcn12788-bib-0044){ref-type="ref"}                                                                                                     GO:0000027\~ribosomal large subunit assembly
  *DOCK5*                                                 Dedicator of Cytokinesis 5                  Familial Parkinson\'s disease -- CNV analysis; DOCK family proteins in multiple neuropsychiatric phenotypes[50](#pcn12788-bib-0050){ref-type="ref"}                              GO:0007264\~small GTPase mediated signal transduction; GO:1900026\~positive regulation of substrate adhesion‐dependent cell spreading
  *PARP14*                                                Poly polymerase family member 14            PTSD, ADHD, MDD -- Genome wide transcriptome[42](#pcn12788-bib-0042){ref-type="ref"}                                                                                             GO:0006355\~regulation of transcription
  *TRMT44*                                                tRNA methyltransferase 44 homolog           Familial epilepsy -- resequencing of linkage region[45](#pcn12788-bib-0045){ref-type="ref"}                                                                                      GO:0030488\~tRNA methylation
  *PM20D1*                                                Peptidase M20 domain containing 1           Parkinson\'s disease -- GWAS[49](#pcn12788-bib-0049){ref-type="ref"}                                                                                                             GO:1901215\~negative regulation of neuron death
  *WDFY4*                                                 WDFY family member 4                        Bipolar Disorder -- GWAS (nominal)[47](#pcn12788-bib-0047){ref-type="ref"}                                                                                                       GO:0016021\~integral component of membrane
  *PARVB*                                                 Parvin beta                                 Schizophrenia -- microRNA interaction[48](#pcn12788-bib-0048){ref-type="ref"}                                                                                                    GO:0007155\~cell adhesion; GO:0031532\~actin cytoskeleton reorganization
  *NBPF11*                                                Neuroblastoma breakpoint family member 11   Schizophrenia -- CNV analysis case--control[52](#pcn12788-bib-0052){ref-type="ref"}                                                                                              No BP annotation

  \(c\) Genes putatively significant to neurobiology                                                                                                                                                                                                                                             
  ---------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------
  *PLXND1*                                             Plexin D1                                                     Neocortical synapse formation[58](#pcn12788-bib-0058){ref-type="ref"}                                                                                                       GO:0007416\~synapse assembly; GO:0048841\~regulation of axon extension involved in axon guidance
  *SETD6*                                              SET domain containing 6                                       Preliminary evidence in memory consolidation through epigenetic regulation[56](#pcn12788-bib-0056){ref-type="ref"}                                                          GO:0048863\~stem cell differentiation; GO:0032088\~negative regulation of NF‐kappaB transcription factor activity
  *NDRG3*                                              NDRG family member 3                                          Highest tissue expression in cerebral cortex and cerebellum[54](#pcn12788-bib-0054){ref-type="ref"}                                                                         GO:0007165\~signal transduction; GO:0030154\~cell differentiation
  *SCUBE3*                                             Signal peptide, CUB domain and EGF like domain containing 3   Mouse knock out model -- neurological behavioral phenotype[55](#pcn12788-bib-0055){ref-type="ref"}                                                                          GO:0051260\~protein homooligomerization; GO:0051291\~protein heterooligomerization
  *CNGB1*                                              Cyclic nucleotide gated channel beta 1                        Upregulated in rat models for cognitive deficits[53](#pcn12788-bib-0053){ref-type="ref"}                                                                                    GO:0051480\~regulation of cytosolic calcium ion concentration; GO:0033365\~protein localization to organelle
  *LRRC8B*                                             Leucine rich repeat containing 8 family member B              Involved in transport of Glutamate, GABA and D‐Serine[57](#pcn12788-bib-0057){ref-type="ref"}; highest tissue expression in brain[54](#pcn12788-bib-0054){ref-type="ref"}   GO:0098656\~anion transmembrane transport
  *C20orf194*                                          Chromosome 20 open reading frame 194                          Highest tissue expression in brain[54](#pcn12788-bib-0054){ref-type="ref"}                                                                                                  
  *ANLN*                                               Anillin actin binding protein                                 Highest tissue expression in brain[54](#pcn12788-bib-0054){ref-type="ref"}                                                                                                  GO:0098609\~cell--cell adhesion

Variant in close proximity to a pathogenic mutation for a Mendelian syndrome.

CNV, copy number variation; EWAS, epigenome wide association study; GO, gene ontology; GWAS, genome‐wide association studies; MIM, Mendelian Inheritance in Man.

Ten other genes that harbored prioritized variants have been implicated in neuropsychiatric syndromes. We identified a variant (rs148371256) in the *NRG2* gene (Neuregulin 2) that was earlier reported to be associated with gamma band oscillations in SCZ with suggestive genome‐wide significance.[39](#pcn12788-bib-0039){ref-type="ref"} The encoded protein neuregulin‐2 has been shown to be critical for the formation and maturation of GABAergic synapses[40](#pcn12788-bib-0040){ref-type="ref"} and its ablation results in dopamine dysregulation.[41](#pcn12788-bib-0041){ref-type="ref"} Another novel variant (chr3:122423522, GRCh37) was identified in the *PARP14* gene (Poly ADP ribose polymerase 14), and the gene has been implicated in post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), and attention deficit hyperactivity disorder (ADHD).[42](#pcn12788-bib-0042){ref-type="ref"} We also noted a variant (rs534059912) in the *GOLM1* gene (Golgi membrane protein 1), which was earlier reported in sporadic Alzheimer\'s dementia (AD) to influence the pre‐frontal cortical volume.[43](#pcn12788-bib-0043){ref-type="ref"} A list of these 10 genes, evidence for disease association, and gene ontology descriptions are presented in Table [2](#pcn12788-tbl-0002){ref-type="table"}(b).[44](#pcn12788-bib-0044){ref-type="ref"}, [45](#pcn12788-bib-0045){ref-type="ref"}, [46](#pcn12788-bib-0046){ref-type="ref"}, [47](#pcn12788-bib-0047){ref-type="ref"}, [48](#pcn12788-bib-0048){ref-type="ref"}, [49](#pcn12788-bib-0049){ref-type="ref"}, [50](#pcn12788-bib-0050){ref-type="ref"}, [51](#pcn12788-bib-0051){ref-type="ref"}, [52](#pcn12788-bib-0052){ref-type="ref"}

Of the remaining genes, there were several with a plausible role in the biology of SMI, but not thus far implicated in any disease phenotype. These genes, with the ontology descriptions and plausible biological implications, are provided in Table [2](#pcn12788-tbl-0002){ref-type="table"}(c).[53](#pcn12788-bib-0053){ref-type="ref"}, [54](#pcn12788-bib-0054){ref-type="ref"}, [55](#pcn12788-bib-0055){ref-type="ref"}, [56](#pcn12788-bib-0056){ref-type="ref"}, [57](#pcn12788-bib-0057){ref-type="ref"}, [58](#pcn12788-bib-0058){ref-type="ref"}

Enrichment of coding variants with plausible functional role in SMI {#pcn12788-sec-0015}
-------------------------------------------------------------------

The NSD‐B set consisted of 248 variants; of these, except for rs570064523 in the *PCSK1* gene, which was identified in cases from two families (G and H), no other overlap at the level of family was noted for the remaining 247 variants (Appendix [S2](#pcn12788-supitem-0002){ref-type="supplementary-material"}, Table S3). In the 'protein domains' category tested using the Interpro database as the source, the term 'epidermal growth factor like domain' showed a nominally significant enrichment with *P* = 0.0013, Benjamini--Hochberg false discovery rate corrected *P* = 0.073. Twelve genes that were enriched for this domain included the *NRG2* and *SCUBE3* genes, which were also categorized in the NSD‐S set along with the *NOTCH1*, *JAG1* and *WIF1* genes, which form critical nodes in the notch signaling pathway implicated in neurodevelopment and embryogenesis (Appendix [S2](#pcn12788-supitem-0002){ref-type="supplementary-material"}, Table S4).[59](#pcn12788-bib-0059){ref-type="ref"} There was no statistically significant enrichment in any of the remaining categories tested with this *in silico* approach.

Discussion {#pcn12788-sec-0016}
==========

The results of our study highlight the usefulness of WES in multiplex families with SMI to identify rare and novel variants that may contribute to the susceptibility to common polygenic syndromes. Many of these variants prioritized by NSD‐S, and presumed to be disruptive, map to genes that have been previously reported in GWAS, candidate gene association, post‐mortem expression, or animal model studies of SMI. In addition, consistent with the WES approach, we identify variants in genes hitherto not reported in the context of an SMI, but that could potentially contribute to disease biology.

The segregation of rare and deleterious variants in Mendelian disease genes with a neuropsychiatric phenotype is in keeping with some recent observations. Studies have shown that heterozygous carriers of Mendelian disease mutations are at increased risk for specific common diseases.[60](#pcn12788-bib-0060){ref-type="ref"} While Mendelian forms of common, complex traits, such as Alzheimer\'s disease, hypertension, hypercholesterolemia, and hypertriglyceridemia, have long been attributed to rare causal variants in single genes, population‐based GWAS in these traits have often implicated genes that also cause single gene disorders.[60](#pcn12788-bib-0060){ref-type="ref"} More recently, using electronic health record data, the disease‐relevant phenotypic burden of rare variants in Mendelian genes, thus far not characterized as 'pathogenic,' has been demonstrated across diverse phenotypes.[61](#pcn12788-bib-0061){ref-type="ref"}

We explored the clinical significance of nine variants in Mendelian genes in the ClinVar database, a publicly available archive of human phenotype‐variation relations.[36](#pcn12788-bib-0036){ref-type="ref"} None of these variants was annotated as 'pathogenic' or 'likely pathogenic' in the database for the corresponding Mendelian phenotype. As a corollary, none of the families had any identified or suspected case of a severe neurodevelopmental syndrome. However, the predicted deleteriousness by *in silico* algorithms, a very low prevalence in the population, physical proximity to known pathogenic mutations, and the reported physiological gene function suggest a plausible role for these variants in the etiology of SMI. The impact of these variants in cellular and/or animal models needs to be examined to validate these observations and to establish their causal role in SMI. Interestingly, an earlier WES study in families with BD also reported variants in genes of monogenic syndromes: holoprosencephaly and progressive myoclonic epilepsy.[13](#pcn12788-bib-0013){ref-type="ref"}

We detected rare variants in 10 additional genes that have been noted in earlier studies to contribute to the risk for polygenic syndromes, such as SCZ, BD, autism, MDD, ADHD, PTSD, AD, and Parkinson\'s disease. This finding is congruent with the evolving concept of shared molecular neuropathology across SMI.[19](#pcn12788-bib-0019){ref-type="ref"} These, along with other identified genes known to be involved in neurodevelopmental processes (e.g., *PLXND1*) or known to have manifold higher brain expression (e.g., *ANLN, LRRC8B*) are potential targets to be examined in future studies of SMI. Lastly, of the 12 genes encoding highly conserved epidermal growth factor‐like domains and showing nominally significant enrichment to this domain, many encode for proteins that play critical roles during embryogenesis and neurodevelopment.[59](#pcn12788-bib-0059){ref-type="ref"}

Certain limitations are to be considered while interpreting the results of this study. The relatively small control set sequenced in our study precluded statistical association testing at the level of a variant or a gene. It has been estimated that rare variant association testing at gene level using case--control samples would require sample sizes greater than 20 000 individuals.[62](#pcn12788-bib-0062){ref-type="ref"} As an alternative, we considered the minor allele frequency of the variant in ExAC South Asian samples in the prioritization approach, and many of the identified variants were noted to be extremely rare. Second, although we sampled a nearly equal number of affected persons from each family, the relationships within pedigrees were not uniform, potentially adding heterogeneity to the number of identified variants. Thus, we prioritized variants with complete sharing allowing for one missing genotype. This resulted in identification of some variants that were not fully penetrant. Third, like the previous studies of WES in SCZ and BD, we have relied on *in silico* predictions to infer the deleteriousness of a variant and have considered those predicted by five algorithms as the primary variants of interest. Supporting this approach, a recent analysis noted that the strength of disease association for a non‐synonymous variant increased with the greater number of deleterious predictions *in silico.* [63](#pcn12788-bib-0063){ref-type="ref"} Fourth, inherent to the prioritization criteria of rarity, deleteriousness and segregation, the NSD‐S and disruptive variant set presented above would explain only a part of an individual\'s liability to disease. The results of this analysis represent the shared familial risk for SMI, private to each pedigree, determined by variants of possible major/moderate effect. Lastly, we have not been able to sample all affected individuals from each multiplex pedigree. Among the unaffected individuals, we have been able to sample one to two representative individuals from five of the pedigrees. Thus, the prioritized variants might represent only a part of the shared genetic risk within each pedigree.

Using WES data in multiplex families with SMI, we find evidence that suggests intersections in the molecular pathways leading to the expression of polygenic SMI and Mendelian neuropsychiatric syndromes. The patient‐derived neural stem cell lines being developed as part of the program[21](#pcn12788-bib-0021){ref-type="ref"} will be useful to explore the functional significance of the identified variants accounting for 'modifier genetic background',[64](#pcn12788-bib-0064){ref-type="ref"} and to characterize mechanisms that underlie the observed genotype--phenotype correlates.

Conclusions {#pcn12788-sec-0017}
-----------

NGS approaches in a family‐based study design are useful to identify novel and rare variants in genes potentially relevant to complex disorders, such as SMI. The study further provides an independent validation for the phenotypic burden of rare deleterious variants in Mendelian disease genes that segregate privately in multiplex pedigrees with SCZ and BD. Our findings support the role of heterogeneity and pleiotropy in the genetic architecture of SMI encompassing a spectrum of neurodevelopmental and degenerative phenotypes.
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